Evidence map›Paper›PMID 37273902›Full record

ArticleMolecular therapy. Methods & clinical development2023

Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation.

Khaled Essawi, Waleed Hakami, Muhammad Behroz Naeem Khan, Reid Martin, Jing Zeng, Rebecca Chu, Naoya Uchida, Aylin C Bonifacino, Allen E Krouse, Nathaniel S Linde and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Peeling back the layers of immunogenicity in Cas9-based genomic medicine.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  4. Review
  5. Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Article
  7. CRISPR/Cas9 Landscape: Current State and Future Perspectives.International journal of molecular sciences · 2023
    Review
  8. Efficient manufacturing and engraftment ofMolecular therapy. Methods & clinical development · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Khaled EssawiDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Gizan, Saudi Arabia.
Waleed HakamiDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Gizan, Saudi Arabia.
Muhammad Behroz Naeem KhanCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Reid MartinDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jing ZengDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Rebecca ChuCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Naoya UchidaCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Aylin C BonifacinoTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD, USA.
Allen E KrouseTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD, USA.
Nathaniel S LindeTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD, USA.
Robert E DonahueCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Gerd A BlobelDivision of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ulrike GerdemannBoston Children's Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Leslie S KeanBoston Children's Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Stacy A MaitlandDepartment of Molecular, Cell and Cancer Biology, Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Scot A WolfeDepartment of Molecular, Cell and Cancer Biology, Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Jean-Yves MetaisDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stephen GottschalkDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Daniel E BauerDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
John F TisdaleCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Selami DemirciCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
National Institutes of Health · USBoston Children's Hospital · USSt. Jude Children's Research Hospital · USJazan University · SAUniversity of Massachusetts Chan Medical School · USChildren's Hospital of Philadelphia · US

Funding

VIROSOME/PROTEOLIPOSOME MEDIATED GENE TRANSFERP01HL053749 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEISS, MITCHELL J · 1994 to 2022
$43.6M
Retroviral Mediated Gene Transfer Into Primate Hematopoietic CellsZIAHL002338 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HONG, SO GUN · 2019 to 2025
$26.3M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
NHLBI NIH HHS P01 HL053749NHLBI NIH HHS R01 HL095791
6 · The paper itself

Abstract

CRISPR-Cas9-based therapeutic genome editing approaches hold promise to cure a variety of human diseases. Recent findings demonstrate pre-existing immunity for the commonly used Cas orthologs from

Indexed as

gene therapygenome editinghematopoietic stem cell transplantationimmunitySaCas9SpCas9

Identifiers

PMID37273902
PMCPMC10236215
OpenAlexW4366483633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.